Skip to main content

Table 1 Use of oral antidiabetes drugs to treat individuals with prediabetes: effect on cardiovascular and diabetes outcomes.

From: Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes

Study

DREAM [94] (Rosiglitazone)

STOP-NIDDM [7,20] (Acarbose)

DPP [5,48]

Patient population

IGT/IFG n = 5269

IGT n = 1368

IGT n = 2155

Effect of intervention on diabetes incidence

-60% (p < 0.0001)

-36.4% (p = 0.003)

-31% (p < 0.01)

Effect of intervention on new hypertension incidence

n/a

-34% (p = 0.006)

+25% (not significant)

Effect of intervention on rate of predefined CV events

+37% (p = 0.08)

-49% (p = 0.03)

n/a

  1. DREAM: Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication. STOP-NIDDM: Study to Prevent Non-Insulin Dependent Diabetes Mellitus. DPP: Diabetes Prevention Program